CUTISS announces positive Phase 2 trial readout for long-term efficacy and safety of denovoSkin™

First-of-its-kind bio-engineered skin therapy continued demonstration that denovoSkin™ can regenerate long-term, improving scar quality and reducing the need for multiple surgeries. It’s positive news: so far the data confirms both efficacy and safety in reconstructive skin surgery and burns, demonstrating that denovoSkin™ delivers sustained improvements in patient outcomes compared to the standard treatment. Next steps – Phase 3 trial underway: With the Phase 3 trial authorized in the EU, CUTISS is moving closer to making denovoSkin™ available to patients, bringing the first personalized, regenerative skin solution to market.